factor XI + platelet glycoprotein (GP) Ib:IX:V complex -> factor XI:platelet glycoprotein (GP) Ib:IX:V complex

Stable Identifier
R-HSA-158145
Type
Reaction [binding]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
This Reactome event describes factor XI (FXI) binding to the glycoprotein Ib complex (GPIb:IX:V, GP1BA:GP1BB:GP9:GP5) on the platelet surface. Specifically, the A3 domain of FXI binds to the leucine-rich repeat in the NH2-terminal of GPIbα (GP1BA), facilitating FXI-platelet association (Baglia FA et al., 2004a, b). Supporting evidence from studies using angiotensin II–infused mice demonstrates that GPIbα-dependent, platelet-localized FXI is essential for thrombin-FXIa feedback activation in vivo (Kossmann S et al., 2017).

Plasma FXI, encoded by the F11 gene, circulates as an inactive homodimeric zymogen, with its subunits stabilized by disulfide bonds (Wu W et al., 2008; Mohammed BM et al., 2018). Unlike other vitamin K-dependent clotting factors, FXI lacks the gamma-carboxyglutamic acid (Gla) domain, a calcium-binding domain essential for a binding to phospholipid membranes. Instead, FXI associates with cell surfaces through receptor-mediated interactions. On the cell surface, FXI is converted to activated factor XI (FXIa) through proteolytic cleavage at Arg387-Ile388 within its protease domain. In the body, this reaction occurs primarily on the surfaces of activated platelets via interactions between FXI and platelet receptors, including glycoprotein Ib (GPIb:IX:V) complex, glycoprotein IV (CD36), and apolipoprotein E receptor 2 (ApoER2) (Greengard JS et al. 1986; Baird TR and Walsh PN 2002; Baglia FA et al., 2004a, b; White-Adams TC et al., 2009; Emsley J et al., 2010; Kossmann S et al., 2017; Mohammed BM et al., 2018; Reitsma SE et al., 2021). Binding to the platelet surface appears to shield FXIa from inactivation by platelet-derived inhibitors (Reitsma SE et al., 2021). Studies showed that while FXI and FXIa can interact with endothelial cell (EC) surface via high molecular weight kininogen (HMWK) or directly in its absence, these interactions do not significantly contribute to thrombin generation (Shariat-Madar Z et al., 2001; Mahdi F et al., 2003; Puy C et al., 2024, reviewed by Pathak M et al., 2018; Lira AL et al., 2024). Additionally, FXI can also be activated upon binding to negatively charged surfaces, such as polyphosphate secreted from the dense granules of activated platelets (Choi SH et al., 2011; Geng Y et al., 2013).

Literature References
PubMed ID Title Journal Year
33471623 Role of platelets in regulating activated coagulation factor XI activity

McCarty, OJT, Tucker, EI, Pang, J, Puy, C, Lorentz, CU, Reitsma, SE, Shatzel, JJ, Gailani, D, Raghunathan, V, Gruber, A

Am J Physiol Cell Physiol 2021
29223926 An update on factor XI structure and function

Cheng, Q, Li, C, Emsley, J, Verhamme, IM, Ivanov, I, Matafonov, A, Dickeson, SK, Sun, MF, Gailani, D, Sun, D, Mohammed, BM

Thromb. Res. 2018
3017409 Binding of coagulation factor XI to washed human platelets

Heeb, MJ, Griffin, JH, Ersdal, E, Greengard, JS, Walsh, PN

Biochemistry 1986
15317813 Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI

Lopez, JA, Walsh, PN, Gailani, D, Baglia, FA

J Biol Chem 2004
Participants
Participates
Orthologous Events
Authored
Created
Cite Us!